Frontiers in medicine · 2026
A novel dual elastography-based model for screening high-risk varices in hepatitis B virus-related cirrhosis.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Xing, Chen Min, Zheng Ying, Yang Xiuhua, Zhang Wei, Zhang Yao, Yin Zhiyong, Liao Jintang, Tang Yangshuo, Yu Jie, Liang Ping, Meng Fankun
Аннотация
BACKGROUND AND OBJECTIVE: Variceal bleeding carries high mortality and recurrence rates, underscoring the urgent need for effective non-invasive tests (NITs) to assess the severity of esophageal varices (EVs) and predict bleeding risk. This study aimed to develop and validate a robust model for safely excluding high-risk varices (HRVs) in patients with hepatitis B virus (HBV)-related cirrhosis and to compare its diagnostic performance and clinical utility with established NITs.
METHODS: Consecutive patients with HBV-related cirrhosis were prospectively recruited from five centers and underwent dual elastography (dual-elasto) within 1 week of esophagogastroduodenoscopy (EGD). A training cohort from four centers was used to identify predictive variables for HRVs, which were analyzed using machine learning to develop the most reliable model. The final model was externally validated in an independent cohort from the fifth center. Diagnostic efficacy and clinical utility were compared across multiple NITs, including the Baveno VI criteria (B6C), expanded Baveno VI criteria (EB6C), platelet-spleen ratio (PSR), and RESIST-HCV criteria (RESIST).
RESULTS: Among 703 screened patients, 328 were enrolled (training cohort n = 184; validation cohort n = 144). Using logistic regression, we developed the DELU model incorporating six variables: platelet count (PLT), alanine aminotransferase (ALT), ascites, portal vein thrombosis (PVT), inverse difference moment (IDM), and liver stiffness (liver Vs). DELU achieved areas under the receiver operating characteristic curve (AUROCs) of 0.822 (training) and 0.779 (validation), outperforming RESIST (0.600 and 0.626) and B6C (0.569 and 0.575). EB6C and PSR were excluded because they exceeded the 5% missed-HRV threshold. DELU demonstrated the highest spared-EGD rates (20.7% training; 11.1% validation) and maintained robust performance across subgroups, including Child-Pugh B/C (AUROC 80.3%), Child-Pugh A (79.7%), antiviral therapy (ART)-treated (82.5%), and virologically suppressed patients (84.6%). Performance was not influenced by hepatocellular carcinoma (HCC) status, sex, or body mass index (BMI).
CONCLUSION: DELU is a reliable and safe non-invasive tool for excluding HRVs in HBV-related cirrhosis, providing superior diagnostic accuracy and significant endoscopy-sparing potential across diverse clinical settings. RESIST may serve as a safe alternative when elastography is unavailable.
CLINICAL TRIAL REGISTRATION: [ClinicalTrials.gov], identifier [NCT04640350].
METHODS: Consecutive patients with HBV-related cirrhosis were prospectively recruited from five centers and underwent dual elastography (dual-elasto) within 1 week of esophagogastroduodenoscopy (EGD). A training cohort from four centers was used to identify predictive variables for HRVs, which were analyzed using machine learning to develop the most reliable model. The final model was externally validated in an independent cohort from the fifth center. Diagnostic efficacy and clinical utility were compared across multiple NITs, including the Baveno VI criteria (B6C), expanded Baveno VI criteria (EB6C), platelet-spleen ratio (PSR), and RESIST-HCV criteria (RESIST).
RESULTS: Among 703 screened patients, 328 were enrolled (training cohort n = 184; validation cohort n = 144). Using logistic regression, we developed the DELU model incorporating six variables: platelet count (PLT), alanine aminotransferase (ALT), ascites, portal vein thrombosis (PVT), inverse difference moment (IDM), and liver stiffness (liver Vs). DELU achieved areas under the receiver operating characteristic curve (AUROCs) of 0.822 (training) and 0.779 (validation), outperforming RESIST (0.600 and 0.626) and B6C (0.569 and 0.575). EB6C and PSR were excluded because they exceeded the 5% missed-HRV threshold. DELU demonstrated the highest spared-EGD rates (20.7% training; 11.1% validation) and maintained robust performance across subgroups, including Child-Pugh B/C (AUROC 80.3%), Child-Pugh A (79.7%), antiviral therapy (ART)-treated (82.5%), and virologically suppressed patients (84.6%). Performance was not influenced by hepatocellular carcinoma (HCC) status, sex, or body mass index (BMI).
CONCLUSION: DELU is a reliable and safe non-invasive tool for excluding HRVs in HBV-related cirrhosis, providing superior diagnostic accuracy and significant endoscopy-sparing potential across diverse clinical settings. RESIST may serve as a safe alternative when elastography is unavailable.
CLINICAL TRIAL REGISTRATION: [ClinicalTrials.gov], identifier [NCT04640350].